New nanoparticle-based drug delivery system improves atherosclerosis treatment

Little (2022). DOI: 10.1002/smll.202200967″ width=”800″ height=”306″/>

Theranostic nanoparticles (NPs) synthesized using n-butylcyanoacrylate (BCA). The air-trapped NPs were synthesized using the sonication-based mini-emulsion method. The BCA monomer is emulsified in the aqueous phase and loaded with 2-hydroxypropyl-beta-cyclodextrin (CD) and indocyanine green (ICG)/IR780 dye. During the generation step, air is trapped in the NPs. DC-loaded NPs injected intravenously accumulate at the atherosclerotic plaque and release DC, reducing plaque size. ICG/IR780 charged and air-trapped NPs provided contrast enhancement via NIR fluorescence and ultrasound imaging. The generated theranostic NPs allow both identification/diagnosis of atherosclerosis and effective anti-atherosclerotic therapy. Credit: Sourabh Mehta et al, Little (2022). DOI: 10.1002/smll.202200967

Baker Heart and Diabetes Institute researchers have designed and developed a new drug delivery method that can significantly improve the effectiveness of a drug used to treat atherosclerosis and has the potential to identify and treat other diseases.

The technique, using drug-loaded nanoparticles, directly targets the site of atherosclerosis in animal models, enhancing cell uptake of the drug hydroxylpropyl-beta-cyclodextrin (CD) and significantly lowering cholesterol levels more effectively than the drug alone.

Currently, high doses of CD are required during the treatment of atherosclerosis, resulting in side effects including hearing loss, but sustained local release of this drug-loaded nanoparticle (CDNP), not only would improve the effectiveness of the drug, but would probably also reduce these negative effects.

The study, led by Baker Institute Deputy Director, Professor of Basic and Translational Sciences, Karlheinz Peter, was published in the journal Little this week.

“We know that DC reduces the cholesterol content of plaque, but it’s difficult to get the drugs to the required area, so you need a large amount,” said co-investigator and director Xiaowei Wang. from the laboratory of the Baker Institute, associate professor of molecular imaging and theranostics. .

“We packaged the drug into the nanoparticle, which can be sent directly to the disease site. Once there, the drug builds up and removes cholesterol.

“We already know that CD is an effective treatment for other diseases, including Alzheimer’s disease and Niemann-Pick type C disease. This technique therefore has the potential to also improve treatment efficacy for these diseases.”

The nanoparticles have the added benefit of a gas core and a fluorescent dye coating, allowing them to be used as a contrast agent for diagnostic imaging, Wang said.

“We can also visualize the nanoparticles using ultrasound, which would be a valuable diagnostic tool, and can burst the drug-filled bubble for immediate drug release using an ultrasound wave,” she said. declared.

“We believe that these CDNPs provide a platform for the diagnostic and therapeutic delivery of anti-atherosclerotic therapy, and that DC support platforms like CDNPs can be used for the co-administration of multiple potent drugs. .”

Development of a new combination of medicinal nanoparticles for atherosclerosis

More information:
Sourabh Mehta et al, An Ultrasound-Responsive Theranostic Cyclodextrin-Loaded Nanoparticle for Multimodal Imaging and Atherosclerosis Therapy, Little (2022). DOI: 10.1002/smll.202200967
Journal information:

Provided by Baker Heart and Diabetes Institute

Quote: New nanoparticle-based drug delivery system improves treatment of atherosclerosis (2022, June 23) Retrieved June 23, 2022 from delivery-treatment-atherosclerosis.html

This document is subject to copyright. Except for fair use for purposes of private study or research, no part may be reproduced without written permission. The content is provided for information only.

Back To Top